Targeting allergies and beyond, biotechnology company Angany is combining immunotherapy and anti-viral approaches for the development of innovative eBioparticles designed to increase ...

The collaboration’s aim is to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. Under the terms of the agreement, Sanofi is to obtain an exclusive ...